The global market for single-cell expression quantitative trait locus (eQTL) clinical workflows is experiencing substantial growth, driven by increased investments in high-resolution genomic analysis by healthcare and life sciences organizations. According to a new report added to ResearchAndMarkets.com’s offerings, the market expanded from $1.82 billion in 2025 to $2.18 billion in 2026, marking a compound annual growth rate (CAGR) of 19.6%1. This growth is attributed to heightened genomics research investments, a rising demand for disease biomarker identification, and a shift from traditional bulk sequencing methods to more advanced clinical workflows.
Forecasts suggest that the single-cell eQTL clinical workflows market will reach $4.51 billion by 2030, with a CAGR of 19.9%. Key factors contributing to this growth include the adoption of single-cell sequencing technologies, the use of artificial intelligence in genomic data analysis, the expansion of personalized medicine programs, and the integration of cloud-based platforms with automated sample and library preparation processes2. Notable trends in the market include high-resolution gene expression mapping, automated workflow pipelines, advanced computational analysis, and predictive biomarker discovery.
Precision medicine is a significant driver of demand for single-cell eQTL clinical workflows. As complex and chronic diseases become more prevalent, there is an increasing need for treatment strategies that are informed by individual genetic and cellular characteristics. Single-cell eQTL workflows enable researchers and clinicians to analyze gene expression variation at the cellular level, identify patient-specific therapeutic targets, and translate genomic data into clinically relevant insights. This capability supports more targeted treatment selection, enhances biomarker development, and strengthens clinical decision-making.
The market’s potential is further underscored by the expansion of personalized treatments. In 2023, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases, up from six in 2022. This trend highlights the growing role of genomic technologies in therapeutic development and reinforces the demand for scalable single-cell analysis workflows.
Innovation in the field is focused on integrating whole-genome sequencing data with single-cell RNA sequencing and computational analysis. For example, in January 2023, Singleron Biotechnologies launched a single-cell eQTL analysis workflow within its sequencing service portfolio. This bioinformatics pipeline leverages single-cell RNA sequencing and whole-genome sequencing data to predict cell-type-specific eQTLs, aiding population studies that require coordinated laboratory and computational capabilities. This approach helps researchers investigate the associations between genetic variation, gene expression, and disease mechanisms.
Strategic acquisitions are also influencing the competitive landscape. In November 2025, QIAGEN N.V. acquired Parse Biosciences Inc. for approximately $225 million. This acquisition expanded QIAGEN’s sample technologies portfolio into scalable, instrument-free single-cell sequencing and bolstered its position in AI-enabled biological research and drug discovery. Parse Biosciences offers single-cell RNA sequencing solutions that generate high-resolution expression data for cell-type-specific eQTL analysis in clinical research3.
Regionally, North America was the largest market for single-cell eQTL clinical workflows in 2025, supported by advanced genomics infrastructure, strong biotechnology investment, and broad adoption of precision medicine. The Asia-Pacific region is expected to be the fastest-growing market during the forecast period, driven by increased sequencing capacity, biomedical research, and healthcare investment. The market analysis covers various regions, including Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, with countries such as Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Russia, South Korea, Spain, Taiwan, the United Kingdom, and the United States being included.
The market is segmented by workflow type, including sample preparation, library preparation, sequencing, data analysis, and other workflow types. Technologies used include ribonucleic acid sequencing, microarray, and polymerase chain reaction (PCR)-based methods. Applications span disease research, drug discovery and development, and personalized medicine, among others. The end-users of these technologies range from hospitals and clinics to research institutes and pharmaceutical and biotechnology companies. The market’s subsegments include various stages of sample and library preparation, sequencing methods, and data analysis techniques, each contributing to the comprehensive understanding and application of single-cell eQTL workflows in clinical settings.
Footnotes:
- The market grew from $1.82 billion in 2025 to $2.18 billion in 2026. Source.
- The market is projected to reach $4.51 billion by 2030, with a CAGR of 19.9%. Source.
- QIAGEN acquired Parse Biosciences for approximately $225 million. Source.
Featured Image: Megapixl @ Ipopba